Monday, 30 January 2023
This website uses cookies. By using our site you agree to our privacy policy

Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Accreditation
    • Contact Us
  • Reference
    • Newsletters
    • FAQ Library
    • COVID-19 Resource Center
    • What are MPNs?
  • Continuing Education
    • Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
  • Resources
    • Articles
    • Tools
  • Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
  • Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies
  • What Are Mpns Banner
  • FAQs Library
  • Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
  • How can the mutational profile in myeloproliferative neoplasms (MPN) help to inform diagnosis and prognosis?
  • How is red blood cell (RBC) transfusion used to manage anemia in myelofibrosis (MF) patients?
  • Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
  • Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies
  • What Are Mpns Banner
  • FAQs Library
  • Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
  • How can the mutational profile in myeloproliferative neoplasms (MPN) help to inform diagnosis and prognosis?
  • How is red blood cell (RBC) transfusion used to manage anemia in myelofibrosis (MF) patients?

What's New

Continuing Education
Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
John O. Mascarenhas, MD and Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
Continuing Education
Beyond Ruxolitinib as the Frontline Standard of Care:
Current and Emerging Second-Line Therapies

Prithviraj Bose, MD; and Andrew Kuykendall, MD
Continuing Education
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
Prithviraj Bose, MD; and John Mascarenhas, MD
FAQ
Other than cytopenias, what are signs that my patient is intolerant to ruxolitinib or a JAK inhibitor?
Sandra Kurtin, PhD, ANP-C, AOCN, FAPO
FAQ
What are the updates from ASH regarding new treatments or new data for patients with myelofibrosis?
John O. Mascarenhas, MD
What are MPNs?
What are Myeloproliferative neoplasms (MPNs)?
FAQ
Can we predict which patients will respond to a JAK inhibitor?
Andrew Kuykendall, MD and Prithviraj Bose, MD
FAQ
How would you define treatment success for your patients with myelofibrosis?
Andrew Kuykendall, MD and Prithviraj Bose, MD
FAQ
As a clinician, what should guide my decision on which second-line therapy to choose for my patients?
Prithviraj Bose, MD
FAQ
What key defining point should community providers be aware of when looking at patients considered to have failed ruxolitinib or have achieved only suboptimal response?
John Mascarenhas, MD
View all FAQs
Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis
What are the updates from ASH regarding new treatments or new data for patients with myelofibrosis?
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
Other than cytopenias, what are signs that my patient is intolerant to ruxolitinib or a JAK inhibitor?

As a clinician, what should guide my decision on which second-line therapy to choose for my patients?

How would you define treatment success for your patients with myelofibrosis?

Beyond Ruxolitinib as the Frontline Standard of Care: Current and Emerging Second-Line Therapies

What key defining point should community providers be aware of when looking at patients considered to have failed ruxolitinib or have achieved only suboptimal response?

Can we predict which patients will respond to a JAK inhibitor?

What are Myeloproliferative Neoplasms (MPNs)?
Untitled Document
MedicalEd Digest
Subscribe Today to join our MedicalEd Digest
mailing list!
Your email address will not be shared with any third party, nor sold.

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMDS.com | ManagingLymphoma.com | PracticalOncologist.com | MediComWorldwide.com

© 2023 MediCom Worldwide, Inc. All rights reserved

  • Privacy, Terms, and Conditions
  • Contact Us